Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499 | Zendy

Mitchell R. Smith | Zendy; Hailun Li | Zendy; Leo I. Gordon | Zendy; Randy D. Gascoyne | Zendy; Elisabeth Paietta | Zendy; Andres ForeroTorres | Zendy; Brad S. Kahl | Zendy; Ranjana H. Advani | Zendy; Fangxin Hong | Zendy; Sandra J. Horning | Zendy

Open Access

Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499

Author(s) -

Mitchell R. Smith,

Hailun Li,

Leo I. Gordon,

Randy D. Gascoyne,

Elisabeth Paietta,

Andres ForeroTorres,

Brad S. Kahl,

Ranjana H. Advani,

Fangxin Hong,

Sandra J. Horning

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.42.2444

Subject(s) - medicine , vincristine , mantle cell lymphoma , rituximab , cyclophosphamide , ibritumomab tiuxetan , radioimmunotherapy , oncology , phases of clinical research , doxorubicin , prednisone , lymphoma , chemotherapy , monoclonal antibody , immunology , antibody

To test the hypothesis that consolidation therapy with yttrium-90 ((90)Y) -ibritumomab tiuxetan after brief initial therapy with four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated mantle-cell lymphoma would be a well-tolerated regimen that would improve outcomes compared with historical R-CHOP data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research